In Reply: We agree with Dr Pazo Cid and colleagues that the clinical utility of doxorubicin in hepatocellular carcinoma is modest at best. At the time of initiation of the study, which is the same period when a randomized phase 3 trial of sorafenib vs placebo was started,1 a placebo control group would have been another choice. However, our decision was to use doxorubicin as our control group, as it has been accepted both as a widely used agent in standard practice and as a regulatory standard.2,3
Abou-Alfa G, Capanu M, Saltz L. Doxorubicin Plus Sorafenib in Treatment of Advanced Hepatocellular Carcinoma—Reply. JAMA. 2011;305(8):781. doi:10.1001/jama.2011.160
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: